Cargando…
The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Society of Pathology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463757/ https://www.ncbi.nlm.nih.gov/pubmed/34567192 http://dx.doi.org/10.30699/IJP.2021.520570.2542 |
_version_ | 1784572464772153344 |
---|---|
author | Arabameri, Nasibeh Heshmatipour, Zoheir Eftekhar Ardebili, Shima Jafari Bidhendi, Zeinab |
author_facet | Arabameri, Nasibeh Heshmatipour, Zoheir Eftekhar Ardebili, Shima Jafari Bidhendi, Zeinab |
author_sort | Arabameri, Nasibeh |
collection | PubMed |
description | BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes. This study aimed to investigate the effect of the mutation in (gyrA, parC) on ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa. METHODS: A total of 140 clinical samples were collected from hospitals. The samples were identified by standard biochemical tests, and the antibiotic resistance was investigated by the disk diffusion method. DNA was extracted from 30 isolates, and PCR was performed. PCR-sequencing was carried out to assess gyrA and parC mutations in drug-resistant isolates. NCBI-Blast and MEGA7 software was used to analyze the nucleotide sequences. RESULTS: 30 clinical isolates were 80% resistant to ciprofloxacin; meanwhile, in 21 samples, mutations were observed. 87/5% of mutations were related to gyrA (Thr83 → Ile), 79/16 % parC (Ser87 → Leu), and 4/18% (Glu91 → Lys). The antibiotic resistance to ciprofloxacin and mutations in gyrA and parC genes in resistant isolates are significantly related to each other (P<0.05). CONCLUSION: The mutations in the gyrA and parC genes play an essential role in resistance to ciprofloxacin in clinical isolates of Pseudomonas aeruginosa. |
format | Online Article Text |
id | pubmed-8463757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Iranian Society of Pathology |
record_format | MEDLINE/PubMed |
spelling | pubmed-84637572021-09-25 The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa Arabameri, Nasibeh Heshmatipour, Zoheir Eftekhar Ardebili, Shima Jafari Bidhendi, Zeinab Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes. This study aimed to investigate the effect of the mutation in (gyrA, parC) on ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa. METHODS: A total of 140 clinical samples were collected from hospitals. The samples were identified by standard biochemical tests, and the antibiotic resistance was investigated by the disk diffusion method. DNA was extracted from 30 isolates, and PCR was performed. PCR-sequencing was carried out to assess gyrA and parC mutations in drug-resistant isolates. NCBI-Blast and MEGA7 software was used to analyze the nucleotide sequences. RESULTS: 30 clinical isolates were 80% resistant to ciprofloxacin; meanwhile, in 21 samples, mutations were observed. 87/5% of mutations were related to gyrA (Thr83 → Ile), 79/16 % parC (Ser87 → Leu), and 4/18% (Glu91 → Lys). The antibiotic resistance to ciprofloxacin and mutations in gyrA and parC genes in resistant isolates are significantly related to each other (P<0.05). CONCLUSION: The mutations in the gyrA and parC genes play an essential role in resistance to ciprofloxacin in clinical isolates of Pseudomonas aeruginosa. Iranian Society of Pathology 2021 2021-07-06 /pmc/articles/PMC8463757/ /pubmed/34567192 http://dx.doi.org/10.30699/IJP.2021.520570.2542 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License, (https://creativecommons.org/licenses/by/4.0/) which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially |
spellingShingle | Original Article Arabameri, Nasibeh Heshmatipour, Zoheir Eftekhar Ardebili, Shima Jafari Bidhendi, Zeinab The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title | The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title_full | The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title_fullStr | The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title_full_unstemmed | The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title_short | The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa |
title_sort | role of gene mutations (gyra, parc) in resistance to ciprofloxacin in clinical isolates of pseudomonas aeruginosa |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463757/ https://www.ncbi.nlm.nih.gov/pubmed/34567192 http://dx.doi.org/10.30699/IJP.2021.520570.2542 |
work_keys_str_mv | AT arabamerinasibeh theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT heshmatipourzoheir theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT eftekharardebilishima theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT jafaribidhendizeinab theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT arabamerinasibeh roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT heshmatipourzoheir roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT eftekharardebilishima roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa AT jafaribidhendizeinab roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa |